Analysts Boost Syndax Pharmaceuticals' Forecasts, Revenue and EPS Estimates Increase

Analysts have upgraded their forecasts for Syndax Pharmaceuticals, with revenue expected to increase 118% to $170m in 2025 and losses narrowing 18% to $3.20 per share. The price target has been raised 6.4% to $34.75. The upgrades reflect a more bullish view on the company's business prospects and its potential to grow faster than its competitors.

Analysts have upgraded their forecasts for Syndax Pharmaceuticals, Inc. (SNDX), projecting a significant increase in revenue and a narrowing of losses for 2025. The upgrades reflect a more optimistic view on the company's business prospects and its potential to outperform competitors.

According to the latest reports, revenue is expected to surge by 118% to $170 million in 2025, a substantial increase from previous estimates. Concurrently, analysts predict that losses will narrow by 18% to $3.20 per share. The price target has been raised by 6.4% to $34.75, indicating a more favorable outlook on the company's stock performance.

Syndax Pharmaceuticals, a biopharmaceutical company specializing in oncology therapeutics, reported its second-quarter 2025 earnings on August 4, 2025, showcasing robust commercial momentum driven by the successful launch of its new products, Revuforj and Niktimvo. Revenue reached $38.0 million, surpassing Wall Street's GAAP estimate of $26.8 million by $11.2 million (41.8%), marking a 985.7% year-over-year increase from $3.5 million in the prior year period [2].

The company's financial highlights include a GAAP net loss per share of $(0.83), a narrower GAAP loss than the analyst consensus for a $(1.02) loss. Revuforj, a menin inhibitor for certain acute leukemias, generated $28.6 million in GAAP net sales in Q2 2025, representing a 43% sequential increase from the previous quarter. Niktimvo, a CSF-1R-blocking antibody for chronic graft-versus-host disease, contributed $9.4 million in collaboration revenue (GAAP) in Q2 2025 from its U.S. launch with partner Incyte [2].

Syndax's strong performance is attributed to its core strategy of bringing innovative oncology drugs with high unmet medical need to market and expanding their uses through clinical trials and regulatory approvals. The company's main success factors include the commercial uptake of Revuforj and Niktimvo, strategic partnerships, and ongoing pipeline development [2].

Looking ahead, Syndax Pharmaceuticals is expected to continue its momentum with promising clinical trial data for Revuforj and ongoing studies for Niktimvo. The company is actively pursuing multiple clinical trials for Revuforj, including pivotal Phase 3 trials and combination studies with standard-of-care agents in various forms of acute leukemia. The FDA granted Priority Review to the company's supplemental New Drug Application for Revuforj for the treatment of relapsed or refractory mNPM1 AML, with a PDUFA target action date of October 25, 2025 [1].

Analysts remain bullish on Syndax Pharmaceuticals' prospects, with the company's strong financial performance and promising pipeline positioning it for continued growth and success in the biopharmaceutical sector.

References:
[1] https://www.tradingview.com/news/tradingview:8d898c35c8a2a:0-syndax-pharmaceuticals-inc-sec-10-q-report/
[2] https://www.nasdaq.com/articles/syndax-sndx-q2-revenue-jumps-986